NEW YORK (GenomeWeb) – GenomOncology said this week that CompanionDX, a CLIA-certified laboratory that specializes in pharmacogenomics, cancer companion diagnostics, and targeted next-generation sequencing, will use its solution to support its suite of next-generation sequencing-based cancer assays.
GenomOncology’s GO Clincal Workbench will help researchers in CompanionDx’s lab "manage increased volume and quickly add new assays to meet the needs of our oncologists" as well as create and deliver "therapy-driven clinical reports," David Lasecki, CompanionDx’s president said in a statement.
Financial and other terms of the agreement were not disclosed.
Last week, GenomOncology said that Cleveland's University Hospitals will use the GO Clinical Workbench to launch its first next-generation sequencing-based cancer diagnostic test.